AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
3don MSN
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback